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Hepatocellular carcinoma (HCC) is a deadly form
of liver cancer that is increasingly prevalent. We
analyzed global gene expression profiling of 361
HCC tumors and 49 adjacent noncancerous liver
samples by means of combinatorial network-based
analysis. We investigated the correlation between
transcriptome and proteome of HCC and recon-
structed a functional genome-scale metabolic model
(GEM) for HCC. We identified fundamental metabolic
processes required for cell proliferation using the
network centric view provided by the GEM. Our anal-
ysis revealed tight regulation of fatty acid biosyn-
thesis (FAB) and highly significant deregulation of
fatty acid oxidation in HCC. We predicted mitoc-
hondrial acetate as an emerging substrate for FAB
through upregulation of mitochondrial acetyl-CoA
synthetase (ACSS1) in HCC. We analyzed heteroge-
neous expression of ACSS1 and ACSS2 between
HCC patients stratified by high and low ACSS1
and ACSS2 expression and revealed that ACSS1 is
associated with tumor growth and malignancy under
hypoxic conditions in human HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a deadly form of liver cancer,
and it is currently the second leading cause of cancer-related
deaths worldwide (European Association For The Study Of The
Liver; European Organisation For Research And Treatment Of
Cancer, 2012). Despite a number of available treatment stra-
tegies, the survival rate for HCC patients is low (Llovet et al.,2014 Cell Reports 13, 2014–2026, December 1, 2015 ª2015 The Aut2008). Considering its rising prevalence, more targeted and
effective treatment strategies are highly desirable for HCC.
Cancer development involves major metabolic alterations
(Carracedo et al., 2013), and the complexity of metabolism has
been captured by the reconstruction of genome-scale metabolic
models (GEMs) (Lewis and Abdel-Haleem, 2013;Mardinoglu and
Nielsen, 2015; O’Brien et al., 2015; Yizhak et al., 2015), one of
the denominators in systems biology, to identify selective anti-
cancer drug targets (Agren et al., 2014; Folger et al., 2011). A
GEM is the collection of all known biochemical reactions occur-
ring in a given healthy cell or cancer, and each of these reactions
is associated with gene products catalyzing these reactions
(Mardinoglu et al., 2013a, 2015; Mardinoglu and Nielsen, 2012;
Oberhardt et al., 2013; Shoaie and Nielsen, 2014). To unveil
the molecular mechanisms underlying cancer, cancer-specific
GEMs have been reconstructed (Agren et al., 2012; Gatto
et al., 2014; Ghaffari et al., 2015; Mardinoglu et al., 2013b; Yizhak
et al., 2014).
Availability of GEMs together with the high-throughput data
andmethods of data analysismay enable increased understand-
ing of the altered metabolism in cancer. In addition, differential
expression (DE) and differential rank conservation (DIRAC)
analysis (Eddy et al., 2010) extract different types of information
from gene expression data and may complement each other.
Here, we identified metabolic differences between 361 HCC tu-
mors and 49 adjacent noncancerous liver tissue samples using
global gene expression profiling (RNA sequencing [RNA-seq]
data). We reconstructed a population-based functional GEM
for HCC tumors by integrating the transcriptome and proteome
of HCC and examined the changes in the gene expression
data using DE and DIRAC analysis based on the network to-
pology provided by the GEM. We performed DIRAC analysis to
identify and measure network-level perturbations based on the
relative levels of expression for participating genes (Figure S1;
Supplemental Experimental Procedures). Finally, we discoveredhors
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Figure 1. Reconstruction of the Functional GEM for HCC Tumor
(A and B) A functional generic GEM for HCC, iHCC2578 is reconstructed based on transcriptome (A) and proteome (B) of the HCC tumors. The distributions of
expression for the protein coding genes are illustrated based on transcriptome (A) and proteome (B) of HCC.
(C and D) All protein coding genes (C) and HMR2 genes (D) that are evaluated as present in HCC based on either in transcriptomics and proteomics data are used
during the reconstruction of the iHCC2578.
(E) The source of evidence for the protein coding genes as well as the associated reactions incorporated into the model is shown.
(F) The content of iHCC2578 is compared with the previously published personalized HCC models that are reconstructed based on proteomics data. iHCC2578
contains all reactions in the personalized GEMs that are included based on HCC proteome.
See also Data S1.heterogeneous expression of the acetate utilizing enzymesmito-
chondrial and cytosolic acetyl-CoA synthetase (ACSS1) and
(ACSS2), respectively, within the HCC patients and compared
the metabolic differences between HCC patients stratified by
high and low ACSS1 and ACSS2 expression.
RESULTS
Defining HCC Proteome
We retrieved RNA-seq data for 361 individuals suffering from
HCC as well as 49 noncancerous liver samples from The Cancer
Genome Atlas database (TCGA). Based on mRNA expression
data in TCGA, we interpreted low-abundance transcripts (tran-
scripts per million [TPM] <10) as not being translated to their
corresponding proteins based on our previous correlation anal-
ysis of transcriptome and proteome (Fagerberg et al., 2014; Va¨r-
emo et al., 2015). We identified 12,792 (62%) of all putative pro-
tein coding genes (20,531) as being expressed in at least three of
the 361 analyzed HCC tumors (Figure 1A; Data S1A). Recently,Cell Rewe presented antibody-based proteome analysis of HCC tumors
obtained from 27 male and female subjects (Agren et al., 2014)
using the antibodies developed in Human Protein Atlas (HPA)
(http://www.proteinatlas.org) (Kampf et al., 2014a, 2014b; Uhle´n
et al., 2015) and hereby identified 11,057 (70%) of the analyzed
15,841 proteins as being present in at least three of the HCC
tumors (Figure 1B; Data S1B). Triplicate evaluations of every
protein and transcript in HCC tumors were performed to avoid
errors in experimental measurements during the identification
of the HCC proteome and transcriptome. From comparison of
two datasets, we found that 7,677 of the all protein coding genes
(Figure 1C) and 1,988 of the protein coding genes in HMR2 (Mar-
dinoglu et al., 2014) (Figure 1D) were consistently present in
HCC. The differences between the coverage of the protein cod-
ing genes in HCC by transcriptome and proteome can be partly
explained by the individual variations between the analyzed HCC
tumors. Our findings were consistent with our previous study,
where we analyzed the protein expression of six HCC patients
and observed large variations between the HCC tumors (Agrenports 13, 2014–2026, December 1, 2015 ª2015 The Authors 2015
et al., 2014). However, such variations can cause limitations
while performing DE analysis to detect altered biological pro-
cesses in HCC compared to noncancerous liver, and we there-
fore reconstruct a consensus GEM for HCC that contains all
possible metabolic reactions expressed in HCC tumors.
Generating a Functional Model for HCC, iHCC2578
In order to study the individual variations between HCC tumors,
we performed network-dependent analysis using DIRAC based
on the same metabolic network topology. In this context, we
reconstructed a population-based functional GEM for HCC
tumors, iHCC2578, using proteome and transcriptome of HCC.
The 56 biological tasks (Data S1C) that represent the common
metabolic functions known to occur in all human cells (e.g., syn-
thesis of cholesterol) as well as the biological task for biomass
growth were complemented to the tINIT algorithm together with
theproteomeand transcriptomeofHCC.Aftermanual evaluation,
the resulting model includes 7,780 reactions, 2,578 associated
genes to those reactions, and 5,584metabolites in eight different
subcellular compartments. The functionality of the iHCC2578
was also tested successfully if themodel can perform large num-
ber of (256) biological tasks that represent the major metabolic
functions that occur in human metabolism (Data S1D).
The reconstructed model covers individual variations in HCC
metabolism if detected in at least three of analyzed HCC tumors.
Genes were incorporated into the model if they showed pres-
ence in HCC tumors based on proteome and transcriptome.
The source of evidence for incorporation of the genes and asso-
ciated reactions are shown in Figure 1E. We observed that only
ten geneswere included into themodel due to the connectivity of
the network, since we had evidence for all putative protein cod-
ing genes based on the transcriptome. We compared the con-
tent of iHCC2578 with the six personalized HCC GEMs that
have been reconstructed based on proteomics data (Agren
et al., 2014) and found that iHCC2578 contains 5,307 (98%) of
the 5,405 reactions shared across all six personalized GEMs
as well as 2,470 additional biochemical reactions (Figure 1F).
We also investigated the reason for not incorporating the remain-
ing 98 reactions in iHCC2578 and found that those 98 reactions
belonging to the personalized GEMs have been included into
models due to the connectivity of the networks.
Distinct Differential Gene Expression Profile in HCC
To reveal the global biological differences between HCC tumors
and noncancerous liver, we first identified differentially ex-
pressed genes (q value < 0.05) and hereby found 5,946 regulated
genes (of 20,528) using differential expression sequencing
(DESeq) (Data S1E). In order to gain more insights about the
altered biological processes in HCC compared to noncancerous
liver, we performed gene set analysis (GSA) for gene ontology
(GO) biological process terms using PIANO R package (Va¨remo
et al., 2013). We found that gene sets including DNA replication,
DNA metabolic process, mitosis, and cell cycle are associated
with upregulated genes, whereas catabolic processes and im-
mune response are associated with downregulated genes in
HCC (Figure S2).
We identified reporter metabolites for revealing the altera-
tions in metabolism using the network structure provided by2016 Cell Reports 13, 2014–2026, December 1, 2015 ª2015 The AutiHCC2578. The reporter metabolites algorithm has been devel-
oped to detect hotspot of the metabolism associated with up
or downregulated genes between two phenotypes (Patil and
Nielsen, 2005). We found that metabolites involved in histone
and DNA methylation, lysine metabolism, l-carnitine synthesis,
and tumor growth are associated with upregulated genes in
HCC. Notably, oxygen was identified as a top reporter metabo-
lite associated with the downregulated genes in HCC suggesting
that oxygen is pivotal. (Figure S3; Data S1F).
In order to find tightly regulated and deregulated parts of
the metabolism in HCC, we performed DIRAC analysis on the
normalized gene expression data using the subsystems in
iHCC2578. DIRAC analysis enabled identification of metabolic
pathways reprogrammed differently in HCC patients and we
predicted a high degree of deregulation of central metabolic
pathways such as the tricarboxylic acid (TCA) cycle, electron
transport chain (ETC), and fatty acid oxidation (FAO). In contrast,
fatty acid biosynthesis (FAB) displayed tight regulation as
defined by high conservation of transcript ordering in HCC, a
rare occurrence since the vast majority of the metabolic path-
ways in cancer display some degree of deregulation. Figure 2
illustrates a summary of the alterations in major metabolic path-
ways in iHCC2578 based on DE and DIRAC analysis. The fold
changes and q values of the genes involved in each metabolic
pathway, from the differential expression analysis are presented
in Data S1G.
Increased De Novo Lipogenesis in HCC
The DIRAC analysis revealed FAB as one of the most tightly
regulated pathways in HCC compared to noncancerous liver.
This indicates that the expression of the genes involved in FAB
showed similar reprogramming in all HCC patients. The DE anal-
ysis also pointed out significant (q value < 0.05) upregulation
of key genes involved in FAB, including fatty acid synthase
(FASN) in HCC tumors. In addition, citrate synthase (CS), which
generates citrate fromacetyl-CoA inmitochondria aswell as ATP
citrate lyase (ACLY), which in turn converts citrate to acetyl-CoA
in the cytosol were significantly (q value < 0.05) upregulated. Key
enzymes involved in FAB as well as enzymes catalyzing its pre-
liminary step were upregulated in HCC indicating that FAB plays
a major role in the proliferation of all HCC tumors.
In growing cells, there is an increased demand for NADPH
to supply reducing equivalents required for biosynthetic pro-
cesses. NADPH required for FAB can be produced through the
conversion of malate to pyruvate in the cytosol by malic enzyme
1 (ME1) and in the pentose phosphate (PP) pathway. Notably, we
found that the expression of ME1 as well as the glucose-6-phos-
phate dehydrogenase (G6PD) catalyzing the rate-limiting step
of the oxidative phase of the PP pathway was significantly
(q value < 0.05) upregulated in HCC. The two genes involved
in the non-oxidative phase of the PP pathway, transketolase
(TKT) and transaldolase 1 (TALDO1), were also significantly
(q value < 0.05) upregulated in HCC. Intermediates of the PP
pathway are also used as precursors for nucleotide biosynthesis,
a metabolic feature essential for tumor growth, and upregulation
of the PP pathway may hence serve the purpose of both
providing additional NADPH as well as precursors for nucleotide
biosynthesis (Figure 2).hors
Figure 2. Major Metabolic Alterations in HCC Compared to Noncancerous Liver Samples
Fatty acid biosynthesis (FAB), the pentose phosphate (PP) pathway, and glycolysis show significant upregulation, whereas FAB showed significant tight
regulation in HCC. Fatty acid oxidation and gluconeogenesis display significant downregulation in HCC. DIRAC analysis pointed out to significant deregulation of
the TCA cycle and the electron transport chain in HCC patients. Generation of acetyl-CoA from acetate by ACSS1 in the mitochondria significantly upregulated in
HCC, andmitochondrial acetate is used as ametabolic fuel for the growth and proliferation of tumors. Arrows are colored, based on the direction of change in the
expression of the corresponding genes associated to the reaction. Blue arrows indicate significant (q value < 0.05) downregulation, whereas red arrows indicate
significant (q value < 0.05) upregulation of the associated genes. The detailed descriptions of the genes and the metabolites are included in the SBMLmodel file.
See also Figures S2 and S3 and Data S1.De novo synthesized FAs can be incorporated into lipid drop-
lets (LDs), the intracellular reservoir of neutral fat, and very low
density lipoproteins (VLDLs) that are exporting neutral fat. We
examined the expression of the genes involved in the formation
of the LDs and VLDLs. Among these genes, perilipins (PLIN1 and
PLIN2) and patatin-like phospholipase domain-containing pro-
teins (PNPLA4, PNPLA7, and PNPLA8) involved in LD formation
as well as microsomal triglyceride transfer protein large subunit
(MTTP), APOB protein, and transmembrane 6 superfamily mem-
ber 2 (TM6SF2) involved in VLDLs secretion were downregulated
in HCC patients (Data S1E). Of note, human naturally occurring
mutations in the PNPLA3 and TM6SF2 proteins confer a robust
susceptibility to chronic liver disease progression (Dongiovanni
et al., 2013, 2014). Taken together, our results indicated funda-Cell Remental changes in fatty acid metabolism of HCC with induction
of FAB that has been linked to tumor growth and proliferation.
Mitochondrial Alterations in HCC
In contrast to FAB, DIRAC analysis revealed highly significant
deregulation of mitochondrial b-oxidation in HCC pointing to
large variation in expression of genes associatedwith thesepath-
ways in HCC patients. The majority of genes involved in FAO
including the acyl-CoA dehydrogenase family (e.g., ACADSB),
the acetyl-CoA acyltransferases (ACAA1 and ACAA2), and
the hydroxyacyl-CoA dehydrogenases (HADH, HADHA, and
HADHB) were significantly (q value < 0.05) downregulated in
HCC tumors (Data S1G). In addition, carnitine palmitoyltrans-
ferase 2 (CPT2) that is responsible for the translocation of fattyports 13, 2014–2026, December 1, 2015 ª2015 The Authors 2017
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Figure 3. Decreased Expressions of Genes Involved in Glutamate
Utilization in HCC
Glutamine is not used to fuel growth and proliferation of tumors in HCC tu-
mors. Even though glutamine uptake is increased in HCC through significant
(q value < 0.05) upregulation of SLC38A1, the expression of the enzymes
catalyzing the subsequent conversion of glutamate to a -ketoglutarate (AKG) in
mitochondria and cytosol are significantly (q value < 0.05) downregulated.
Blue arrows indicate significant (q value < 0.05) downregulation, whereas red
arrows indicate significant (q value < 0.05) upregulation of the associated
genes.acyl-CoA esters from the cytosol to the mitochondria was signif-
icantly (q value<0.05) downregulated. Further on,DEanalysis re-
vealed FAO as one of the pathways with the highest degree of
downregulation in HCC.
The DIRAC analysis also revealed the TCA cycle and the elec-
tron transport chain (ETC) as two of the pathways with highest
degree of deregulation in HCC. Interestingly, the majority of the
genes in the TCA cycle displayed no differential expression,
thus the DIRAC algorithm detected possible dysfunction of the
TCA cycle not obviously related to upregulation or downregula-
tion of the enzymes. Significant downregulation of succinate de-
hydrogenase genes (SDHA, SDHB, and SDHD) also displayed
dysfunction of the ETC both in terms of deregulation and down-
regulation (Data S1G).
Pyruvate connects glycolysis to the TCA cycle and it is trans-
ported from cytosol to the mitochondria with the mitochondrial
pyruvate carrier proteins (MPC1 and MPC2) (Herzig et al.,
2012). Loss of eitherMPC1 orMPC2 results in defective pyruvate2018 Cell Reports 13, 2014–2026, December 1, 2015 ª2015 The Autcarrier activity thus suggesting both genes are needed to form a
functioning carrier protein (Herzig et al., 2012). We found that
MPC1 was significantly (q value < 0.05) downregulated in HCC
tumors. With the loss of MPC activity in HCC, pyruvate would
not be able to enter the mitochondria and thus inhibit oxidative
phosphorylation of pyruvate, even in the presence of oxygen.
MPC also provides an important link between glycolysis and
gluconeogenesis since pyruvate entering the mitochondria is
the end point of glycolysis and the starting point of gluconeogen-
esis. As in the Warburg effect, some of the glycolytic genes
showed significant upregulation in HCC, whereas gluconeogen-
esis displayed downregulation and apparent dysfunction (Data
S1G). The first step in gluconeogenesis is the conversion of
oxaloacetate (OAA) to phosphoenolpyruvate (PEP). This reaction
is catalyzed by the enzyme phosphoenolpyruvate carboxyki-
nases, PCK1 and PCK2, that were significantly downregulated
in HCC. The conversion of fructose 1,6-bisphosphate to fructose
6-phosphate catalyzed by the enzyme fructose-1,6-bisphos-
phatase 1 (FBP1) that constitutes a key regulatory step in gluco-
neogenesis was also significantly downregulated in HCC.
Repression of the MPC could, however, be offset by gluta-
mine-based anaplerosis of the TCAcycle. Glutaminemetabolism
also displayed alterations in HCC (Figure 3), with apparent high
uptake of glutamine through upregulation of sodium-coupled
neutral amino acid transporter 1 (SLC38A1) but suppressed
conversion of glutamate to a-ketoglutarate (AKG) through down-
regulation of glutamate dehydrogenases (GLUD1 and GLUD2),
glutamic-oxaloacetic transaminases (GOT1 and GOT2), and glu-
tamic-pyruvate transaminases (GPT1 andGPT2) (Figure 4A). Our
results indicated that glutamine carbon may not actively oxidize
in the TCA cycle in HCC tumors based on the expression of the
genes utilizing glutamine, and this behavior differs from the pro-
posed role of glutamine as an anaplerotic substrate for the TCA
cycle in certain cancers (Le et al., 2012; Metallo et al., 2012;
Mullen et al., 2012).
Mitochondrial Acetate Is Predicted as a Substrate
in FAB
In mammalian cells, the acetyl-CoA used for FAB and histone
acetylation is primarily supplied by mitochondria-derived citrate
(Wellen et al., 2009). Mitochondrial acetyl-CoA is generally pro-
duced by the degradation of lipids and proteins or the conversion
of pyruvate to acetyl-CoA in the mitochondria. Our analysis re-
vealed deregulation and downregulation of b-oxidation as well
as attenuation of MPC function in HCC. In addition, the potential
incorporation of glutamine to citrate via anaplerosis of the TCA
cycle was downregulated in HCC. Therefore, the main source
of mitochondrial acetyl-CoA did not result from any of these
pathways in HCC.
We predicted mitochondrial acetate as an alternative sub-
strate for FAB in HCC tumors based on the expression of the
genes. Acetate can be converted to acetyl-CoA bymitochondrial
ACSS1 and ACSS3 or cytosolic ACSS2 (Figure 2). The expres-
sion of ACSS1 was significantly upregulated in HCC compared
to noncancerous liver (Figure 5A). In contrast, we did not detect
any significant changes in the expression of ACSS2 nor ACSS3
between HCC and noncancerous liver samples (Figure 5A). The
mRNA expression of the ACSS1 and ACSS2 has also beenhors
AB
Figure 4. Expressions of the Enzymes Involved in Glutamate Utilization in HCC Patients
mRNA expression of the enzymes involved in the conversion of glutamate to a-ketoglutarate (AKG) including GPT, GPT2, GOT1, GOT2, GLUD1, and GLUD2 are
shown in (A) HCC patients and noncancerous liver samples as well as (B) in HCC patients stratified by high and low ACSS1 expression. (*q value < 0.05).
See also Figures S4 and S5 and Data S1.measured in healthy liver as well as other major human tissues,
and it has been shown that ACSS1 has low, whereas ACSS2
has high, expression in the healthy liver tissue (Kampf et al.,
2014a; Uhle´n et al., 2015).
We also investigated the differences in the expression of the
genes catalyzing production of acetate within HCC tumors to
detect a possible source of acetate within the HCC tumors. We
did not detect any changes in the expression of genes that pro-
duce acetate in HCC (Data S1G). Hence, we hypothesized that
the acetate potentially used by HCC tumors may be taken up
from the plasma of the subjects.
Stratification of HCC Patients Based on the Expression
of ACSS1
We found significant upregulation of ACSS1, but neither ACSS2
nor ACSS3 in HCC compared to noncancerous liver samples
(Figure 5A). However, upon closer inspection, we observed
that the expression of ACSS1 varied substantially between
HCC patients. Therefore, we compared the global gene expres-Cell Resion profiling of the HCC tumors in the top tenth percentile with
highest expression of ACSS1 (n = 36) with the quartile of HCC tu-
mors (n = 90) with the lowest expression of ACSS1 to understand
its key role in cancer progression. The average expression of
the top tenth percentile was 35.1 transcripts per million (TPM)
compared to the lowest quartile with average expression of 1.0
TPM (Figure 5B). The top tenth percentile was selected as these
tumors clearly displayed ACSS1 expression values far above the
normal range, whereas the lowest quartile was selected because
of the very low expression of ACSS1, yet relatively large sample
size.
DE analysis revealed 3,814 genes (Data S1H) being signifi-
cantly (q value < 0.05) differentially expressed between these
groups, indicating substantial differences between HCC tumors
stratified by high and low ACSS1 expression. Such large hetero-
geneity in gene expression in HCC is consistent with our earlier
study on HCC (Agren et al., 2014). It should be noted that we
did not detect any significant differences in the expression of
ACSS2 within these patients (Figure 5B). We performed GSAports 13, 2014–2026, December 1, 2015 ª2015 The Authors 2019
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Figure 5. Mitochondrial Acetate Supports Tumor Growth under Hypoxia
mRNA expression of the ACSS1, ACSS2, and ACSS3, converting acetate to acetyl-CoA (A and B), CENPF, FOXM1, indicating aggressive HCC tumor growth (C
and D), and HIF1A (E and F). A tell-tale sign of hypoxia is shown in HCC patients and noncancerous liver samples as well as in HCC patients stratified by high and
low ACSS1 expression, respectively (*q value < 0.05).
See also Figures S4 and S5 and Data S1.between the high and low ACSS1-expressing HCC patients
based on GO BP terms and revealed biological processes
related to cell proliferation being associated with upregulated
genes and major catabolic processes being associated with
the downregulated genes (Figure S4). We also identified oxygen
as one of the top reporter metabolites associated with down-
regulated genes in HCC patients with high ACSS1 expression
compared to low ACSS1 expression (Figure S5; Data S1I).
Hence, we predicted that increased expression of ACSS1 is
associated with repression of oxygen-consuming reactions in
the HCC tumor microenvironment based on gene expression
data.
We further investigated if any of the derangements in central
metabolic pathways between HCC and noncancerous liver
were also present between HCC patients stratified by high and
low ACSS1 expression. The majority of the genes involved in
FAO were significantly downregulated in tumors with high
ACSS1 expression compared to low ACSS1 expression (Data2020 Cell Reports 13, 2014–2026, December 1, 2015 ª2015 The AutS1G). In addition, GSA revealed FAO as significantly downre-
gulated. This indicated that the clear general suppression of
FAO found in HCC is further exacerbated in patients with high
ACSS1 expression possibly due to the limited oxygen as is often
seen in the microenvironment of a tumor.
The enzyme pyruvate kinase (PKM) was significantly (q value <
0.05) upregulated in HCC patients with high ACSS1 expression.
We found that expression of PKMwas increased4-fold in HCC
compared to noncancerous liver and further increased 5-fold
in patients with high ACSS1 expression. Upregulation of PKM
may result in increased ability of metabolic adaptation to varying
nutrient and oxygen concentrations. The isoform PFKP of the
enzyme catalyzing the committed step of glycolysis was also
significantly (q value < 0.05) upregulated in patients with high
ACSS1 expression supporting further increased glycolytic flux
in these patients. On the other hand, PCK1 and PCK2 involved
in gluconeogenesis were downregulated, indicating further sup-
pression of this pathway (Data S1G).hors
We also found that all genes involved in glutaminolysis and
glutamate utilization were significantly downregulated in patients
with high ACSS1 expression compared to low ACSS1 expres-
sion (Figure 4B). For instance, the expression of GPT2 was
further suppressed in HCC patients with high ACSS1 expression
and decreased 5-fold, whereas its expression decreased 2-
fold in HCC tumors compared to noncancerous liver samples.
Tumor Growth under Hypoxic Condition Is Associated
with Increased ACSS1 Expression
GO BP terms including cell proliferation, regulation of cell
proliferation, positive regulation of cell proliferation, cell-cycle
process, system development, and organ development are
associated with upregulated genes in HCC patients with
high ACSS1 expression (Figure S4). We also investigated the
changes in the expression of transcription factor forkhead box
M1 (FOXM1) and centromere protein F (CENPF). CENPF is
involved in mitosis, and its increased expression was positively
correlated with venous invasion, advanced differentiation stage,
and a shorter overall survival in HCC patients (Dai et al., 2013).
FOXM1 has been shown to be a proliferation-specific transcrip-
tion factor related to HCC cell growth (Luo et al., 2014). CENPF
and FOXM1, which were two of the most significantly upregu-
lated genes in HCC compared to noncancerous liver (Figure 5D),
were further upregulated in tumors with high expression of
ACSS1 (Figure 5C). Thus, increased expression of FOXM1 and
CENPF may likely serve as an indicator of active proliferation in
patients with high ACSS1 expression.
The above metabolic alterations in HCC patients with high
expression of ACSS1, particularly suppression of FAO and
increased PKM, have previously been related to hypoxia and
increased de-differentiation of HCC tumors (Tanaka et al.,
2013). Increased de-differentiation is a sign of malignancy,
increased growth rate, and invasiveness of a tumor. These fea-
tures have, in turn, been related to hypoxia, likely because a
rapidly growing tumor outgrows vasculature and thus induces
a hypoxic environment. A tell-tale sign of hypoxia is increased
expression of hypoxia-inducible factor 1 a (HIF1A). Indeed,
HIF1A was significantly (q value < 0.5) upregulated in HCC
patients with high ACSS1 expression compared to low ACSS1
(Figure 5F). Interestingly, HIF1A was not differentially expressed
between HCC and noncancerous liver (Figure 5E). This may indi-
cate that oxygen tension varies between HCC patients and is
related to expression of ACSS1 as well as other metabolic alter-
ations observed between patients with high and low expression
of ACSS1. Cancer proliferates and activates a hypoxic response
program that comprises enhanced glycolysis, reduced glucose
entry into the TCA cycle, and upregulation of glutaminolysis.
However, we found that glutamate utilization was also downre-
gulated in HCC patients with high ACSS1 expression, and ace-
tate in the mitochondria was likely to contribute to citrate and
lipogenic acetyl-CoA under hypoxic conditions.
Moreover, we calculated pairwise Spearman correlation
coefficients (r) between the mRNA expressions of the ACSS1,
FOXM1, CENPF, and HIF1A in HCC tumors. We found that the
expression of ACSS1 significantly (p value < 0.001) positively
correlated with the expression of the FOXM1, CENPF, and
HIF1A (r = 0.38, 0.37, and 0.39, respectively).Cell ReStratification of HCC Patients Based on the Expression
of ACSS2
We also stratified the HCC patients based on the expression of
ACSS2 to understand its critical role in the development of
HCC tumors. We compared the global gene expression profiling
of the HCC tumors in the top tenth percentile with the highest
expression of ACSS2 (n = 36) with the quartile of HCC tumors
(n = 90) having the lowest expression of ACSS2 and identified
only 255 significantly (q value < 0.05) differentially expressed be-
tween these groups (Data S1J). Our analysis displayed minor
biological differences between HCC patients stratified based
on the expression of ACSS2 compared to patients stratified by
the expression of ACSS1.
We performed GSA based on GOBP terms and found that cell
proliferation, regulation of cell proliferation, system develop-
ment, and mitosis were associated with downregulated genes.
Fatty acid biosynthetic and metabolic process, steroid biosyn-
thetic process, bile acid metabolic process, and other biosyn-
thetic processes were associated with upregulated genes in
patients with high ACSS2 expression (Figure S6). GO BP terms
(i.e., cell proliferation and regulation of cell proliferation) asso-
ciated with downregulated genes in HCC patients with high
ACSS2 expression were identified as GO BP terms associ-
ated with upregulated genes in HCC patients with high ACSS1
expression. We also identified reporter metabolites and found
that oxygen and other metabolites involved in steroid, arachido-
nate, leukotriene, and bile acidmetabolismwere associated with
upregulated genes, and metabolites involved in glycosphingoli-
pidmetabolismwere associated with downregulated genes (Fig-
ure S7; Data S1K). It should be noted that reporter metabolites
(i.e., oxygen, estrone, testosterone, and arachidonate) associ-
ated with upregulated genes in HCC patients with high ACSS2
expression were also identified as reporter metabolites in HCC
patients with high ACSS1 expression but associated with down-
regulated genes (Figure S5).
We found that FASN was significantly upregulated in HCC pa-
tients with high ACSS2 expression (Data S1G). Interestingly, we
also found that ACADL, ACOX2, and EHHADH involved in FAO
were significantly upregulated in patients with high ACSS2
expression that was a complete opposite phenotype in patients
with high ACSS1 expression. Moreover, PCK2 involved in gluco-
neogenesis was upregulated, and there were no transcriptional
changes in glycolysis in HCC patients with high ACSS2 expres-
sion. Hence, we observed that acetyl-CoA produced by the FAO
may be used as a substrate for FAB in patients with high ACSS2
expression based on gene expression data.
We found that none of these genes involved in glutamine utili-
zation including GLUD1, GLUD2, GOT1, GOT2, GPT1, andGPT2
were significantly differentially expressed between the HCC
patients with high and low ACSS2 expression indicating that
the increased expression of ACSS2 has no effect on the utiliza-
tion of the glutamine (Data S1G). We finally calculated pairwise
Spearman correlation coefficients between the expression of
the ACSS2, FOXM1, CENPF, and HIF1A in HCC tumors. We
found that the expression of ACSS2 was not correlated with
the expression of the FOXM1 and CENPF (p value = 0.35 and
0.45, respectively) and significantly (p value < 0.01) negatively
correlated with the expression of the HIF1A (r = 0.16).ports 13, 2014–2026, December 1, 2015 ª2015 The Authors 2021
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B C D Figure 6. Induction of ACSS1 in Murine and
Human HCC Samples
(A–D) mRNA expression of the Foxm1 (A), Acss1,
and Acss2 (B) is measured in six pooled wild-type
HCC tumor and noncancerous samples using
RNA-seq. The mRNA expression of the ACSS1 (C)
as well as the FOXM1, HIF1A, and CENPF (D) is
measured using RNA-seq in tumor and noncan-
cerous liver samples obtained from four indepen-
dent HCC patients.
(E) Immunohistochemical staining of the proteins
(ACSS1, ACSS2, HIF1A) in five human HCC tu-
mors are presented. Protein expression is seen in
brown, counterstaining in blue.Induction of ACSS1 in Murine and Human HCC Samples
Endocannabinoids acting on hepatic cannabinoid receptor-1
(CB1R) promote de novo lipogenesis (Osei-Hyiaman et al.,
2005) and inhibit FAO in the liver (Osei-Hyiaman et al., 2008).
OnceCB1R
+/+ andCB1R
/ littermates in C57BL/6J background
were injected with 25 mg/kg of DEN (Sigma) at 2 weeks after
birth, the presence of the HCC tumor was verified, and its size
was measured with MRI in each DEN-treated mouse 8 months
after the DEN administration (Mukhopadhyay et al., 2015).
Importantly, activation of hepatic CB1R also promotes the init-
iation and progression of chemically induced HCC in mice, in
which CB1R were found to be overexpressed in tumor versus
non-tumor tissue (Mukhopadhyay et al., 2015). The expression
of FoxM1 was significantly (p value < 0.05) increased 5.4-fold
in wild-type HCC tumor compared to noncancerous samples
obtained from CB1R
+/+ mice (Figure 6A). Moreover, nuclear
localization of FoxM1 was observed in HCC tumor samples ob-
tained from CB1R
+/+ mice.
Interestingly, the expression of CNR1, the gene encoding the
human CB1R, was significantly increased 6.5-fold (q value <
0.05) in HCC tumors compared to noncancerous liver sam-
ples. Moreover, the expression of the CNR1 was significantly
increased 3.7-fold (q value < 0.05) in HCC tumors with high
ACSS1 compared to lowACSS1 expression, whereas its expres-2022 Cell Reports 13, 2014–2026, December 1, 2015 ª2015 The Authorssion was not changed between the tu-
mors with high and low ACSS2. Because
of these intriguing parallels, we retrospec-
tively analyzed the mRNA expression
levels of Acss1 and Acss2 in the HCC
and noncancerous liver samples obtained
from wild-type and CB1R
/ mice (Mu-
khopadhyay et al., 2015). We found that
the expression of Acss1 is increased
17.5-fold, whereas the expression of the
Acss2 is increased 7.8-fold in a pooled
wild-type HCC tumor compared to
noncancerous samples (Figure 6B), and
the expression in CB1R
/ mice was at
or below the detection limit both in HCC
and adjacent noncancerous samples.
We measured the mRNA expression
of the ACSS1 in four independent hu-
man HCC tumor samples and adjacentnoncancerous liver samples (Mukhopadhyay et al., 2015) and
found that its expression was increased 3.6-fold in human
HCC tumors (Figure 6C). The expressions of FOXM1, HIF1A,
and CENPF were also increased 34-fold, 4.1-fold, and 8.8-fold,
respectively, in these human HCC samples (Figure 6D). More-
over, we analyzed protein expression level of ACSS1, ACSS2,
and HIF1A using the antibodies generated in the HPA project
including HPA041014, HPA004141, and HPA001275, respec-
tively, (Uhle´n et al., 2010, 2015) in five additional independent hu-
man HCC tumor samples. We observed that ACSS1 had moder-
ate/strong protein expression levels in the mitochondria,
whereas ACSS2 had none/low protein expression level in the
cytosol. Moreover, we found that HIF1A had moderate/strong
protein expression levels in HCC tumors. Protein expression
levels in HCC tumors as detected by using immunohistochem-
istry (IHC) are presented in Figure 6E.
DISCUSSION
We demonstrated that HCC tumors may have completely
opposite metabolic programming, and stratification of HCC pa-
tients is highly desirable for development of effective treatment
strategies. In this context, we analyzed the global gene expres-
sion profiling of HCC and noncancerous liver using DE and
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Figure 7. Pathophysiology of HCCwith High
ACSS1 Expression
Mitochondrial acetate is used to fuel the fatty acid
biosynthesis (FAB) that is required for HCC tumor
growth and proliferation under hypoxic conditions.
The amount of the fatty acids (FAs) stored in the
lipid droplets (LDs) as well as FAs incorporated
into very low density lipoproteins (VLDLs) are
decreased in HCC tumors.DIRAC analysis based on the network topology provided by
iHCC2578. Reported metabolic alterations in HCC conspired
to a metabolic phenotype supporting cell growth with induction
of FAB for production of cell membrane material, high glycolytic
flux providing glycolytic intermediates for additional macro-
molecular biosynthesis, and production of growth-supporting
NADPH. We observed significant downregulation of gluconeo-
genesis as well as highly significant deregulation of the FAO,
glutamate utilization, TCA cycle, and ETC in HCC tumors we
have analyzed.
Previously, the targetable metabolic vulnerability of ACSS2
has been proposed in a wide spectrum of tumors, including liver
cancer, in several studies (Comerford et al., 2014; Mashimo
et al., 2014; Schug et al., 2015). However, the expression of
ACSS2 is equally expressed both in HCC tumors and noncan-
cerous liver samples and showed no differential expression in
human HCC tumors. In contrast, we found that the expression
of ACSS1 is significantly upregulated in HCC, which suggests
an increased generation of acetyl-CoA from acetate in the mito-
chondria. Mitochondrial acetate emerged as a possible sub-
strate for the increased FAB and had a major role in the growth
and proliferation of HCC tumor.
To identify the role of ACSS1 in the development of HCC, we
stratified the HCC patients based on the level of ACSS1 expres-
sion and identified the metabolic differences between these
patients. We predicted that the expression of ACSS1 is associ-
ated with increased tumor growth and malignancy of HCC under
hypoxic conditions. We also demonstrated increased mRNA
expression of ACSS1 in murine and independent human HCC
samples compared to adjacent noncancerous liver samples as
well as the strong/moderate protein expression of the ACSS1
and HIF1A in additional independent human HCC samples.
Radiolabeled acetate is incorporated into the lipid soluble
fraction of cancer cells (Yoshimoto et al., 2001), and acetate isCell Reports 13, 2014–2026, Dused as a substrate for FAB. The treat-
ment of prostate cancer cells with a
FASN inhibitor resulted in reduced ace-
tate uptake, thus there is a clear asso-
ciation between FASN expression and
acetate uptake (Vavere et al., 2008).
Based on the associations between high
acetate uptake and increased cell growth
and/or malignancy of HCC, we predicted
that acetate uptake may cause more
glucose-derived carbon to be available
for macromolecular biosynthesis and his-
tone modification. This may result in twophenomena: growth when glucose is limited and a more rapid
growth when glucose is abundant. In other words, acetate as
an extra carbon source would serve to relieve the demand for
glucose-derived carbons for lipid production.
We presented the pathophysiology of HCC tumors with
high ACSS1 expression in Figure 7. Our study highlighted the
possible role of mitochondrial acetate as a carbon source for
lipid production in HCC. If FOXM1 and CENPF are drivers of ma-
lignancy in HCC, a connection between high ACSS1 expression
and increased growth and malignancy exists. Further on, signif-
icant positive correlation between increased ACSS1 expression
and HIF1A is obtained from our analyses. Indeed, we predicted
that high acetate uptake may result in increased cell growth
and/or malignancy of HCC under hypoxic conditions. Acetate
uptake in cancer cell lines also increase when subjected to hyp-
oxia (Yoshii et al., 2009), and radiolabeled glucose and acetate
showed a complementary uptake pattern in HCC patients in vivo
(Yun et al., 2009). These two observations indicate a heteroge-
neous uptake of glucose and acetate within the same tumor.
Taken together with the results of the present study, this could
indicate that there is clear association between increased tu-
mor growth, malignancy, hypoxia, and acetate uptake between
different HCC patients but also between different parts of the
same tumor.
Previously, Yun et al. (2009) observed that ACSS1 was highly
expressed in SNU 449 cells (human HCC cell lines from the
Korean Cell Line Bank) with high uptake of labeled acetate up-
take and suggested the use of mitochondrial acetyl CoA for
lipid synthesis. In order to show the effect of ACSS1 on acetate
uptake and cell viability, the authors inhibited ACSS1 using
corresponding small interfering RNA (siRNA) in SNU 449 cells.
Hereby, they found that the amount of acetate uptake and
viability of the cells was reduced more in wells with ACSS1
siRNA than in the well with a control siRNA.ecember 1, 2015 ª2015 The Authors 2023
In linewith our earlier study onHCC (Agren et al., 2014), we find
that there is a large heterogeneity in the metabolism of HCC.
Upregulation of ACSS1 or ACSS2 is consistent in the majority
of theHCCpatients studied here, but still the level of upregulation
varies, and this allows for stratification of the subjects based
on ACSS1 or ACSS2 gene expression. This again points to the
importance of stratification of HCC patients and that there may
only be a few targets that consistently prevent tumor growth.
The findings in the liver of wild-type mice with chemically
induced HCC are similar to those in the human HCC tumor
compared to noncancerous liver, and the marked overexpres-
sion of FOXM1 in human HCC is also similar to that reported
earlier for mouse HCC (Mukhopadhyay et al., 2015). This parallel
is further extended by the similarmarked upregulation ofCNR1 in
HCC tissue in both species. It is tempting to speculate that the
metabolic phenotype of human HCC established in the present
study is functionally linked to increased CB1R activity. Such a hy-
pothesis is supportedby thedata fromCB1R
/mice inwhich the
absence of CB1R was associated with the absence of a detect-
able upregulation of lipogenic gene expression. This, and the
reduced rate of tumor initiation and growth in CB1R
/ mice,
could warrant exploring the possible use of CB1R antagonists
as part of the pharmacotherapy of HCC. Although currently there
are no CB1R antagonists available for human use following the
withdrawal of rimonabant due to neuropsychiatric side effects
(Le Foll et al., 2009), non-brain-penetrant CB1R antagonists
with therapeutic efficacy via peripheral CB1R blockade are
currently being developed (Cinar et al., 2014; Tam et al., 2012).
In conclusion, we studied the individual variations in acetate
utilization between HCC tumors and shed light on the molec-
ular and cellular mechanisms underlying HCC using a systems
biology approach. Expression of ACSS1 clearly correlated with
substantial alterations of the HCC transcriptome as indicated
by the large number of significantly differentially expressed
genes between HCC patients stratified by high and low ACSS1
expression. We predicted that metabolic alterations related to
high ACSS1 expression in HCC patients, (e.g., decreased FAO,
glutamine utilization, gluconeogenesis, and increased glycol-
ysis) are symptoms of an underlying increased growth under
hypoxic conditions. We suggest that inhibition of ACSS1
together with ACSS2 may be used in development of effective
treatment strategies for HCC patients. Lastly, the results of our
systems-level analysis may open novel avenues for understand-
ing the mechanism underlying HCC and may be used in devel-
oping potential treatments.EXPERIMENTAL PROCEDURES
Reconstruction of the Functional GEM for HCC, iHCC2578
We reconstructed a functional GEM for HCC tumors, iHCC2578 that covers
the individual metabolic variations between all HCC patients. The model was
reconstructed based on the proteome and transcriptome of HCC through
the use of largest generic human model, Human Metabolic Reaction database
2 (HMR2) (Mardinoglu et al., 2014) and tINIT algorithm (Agren et al., 2014).
Common biological tasks known to occur in all human cells as well as the
growth as an additional task were used as an input to tINIT algorithm to ensure
the functionality of the model. The tINIT reconstructed model was manually
evaluated, and the final model was tested to see if it could successfully
perform the known metabolic functions in HCC. For instance, non-essential2024 Cell Reports 13, 2014–2026, December 1, 2015 ª2015 The Autfatty acids and amino acids can be synthesized in the model and used as sub-
strate for the tumor growth. iHCC2578 is publically available in the Systems
Biology Mark-up Language (SBML) format as well as in mat file format at Hu-
man Metabolic Atlas (http://www.metabolicatlas.org).
Differential Expression Analysis
RNA-seqV2 gene expression data from 361 HCC samples and 49 adjacent
noncancerous liver samples were downloaded from the TCGA using the
TCGA-assembler R package (Zhu et al., 2014). The analysis of RNA-seq
data was performed using the differential expression sequencing (DESeq)
R-package (Anders and Huber, 2010). Normalization and variance estimation
was performed according to the DESeq manual before subsequent DE anal-
ysis. P values were adjusted for multiple-testing with the procedure of Benja-
mini and Hochberg to calculate q values, and 5,946 genes (of 20,530) were
found to be significantly differentially expressed at a false discovery rate
(FDR) of 5% (q value < 0.05) between HCC and noncancerous liver samples.
DE analysis revealed 3,814 and 255 genes being significantly (q value <
0.05) differentially expressed between the HCC patients stratified by high
and low ACSS1 and ACSS2 expression, respectively.
The DIRAC Algorithm
The DIRAC analysis is a network-based approach, but it is specifically
designed to take into account the combinatorial nature of gene interactions
within the network (Eddy et al., 2010). DIRAC provides quantitative measuring
of how network rankings differ among networks for a given phenotype or
among phenotypes for a given network (e.g., differences in the pathways of
a given GEM) based on the transcriptome of individuals (Figure S1). The
network was defined as being (tightly/loosely) regulated based on the level
of (high/low) conservation of transcript ordering in the transcriptome of individ-
uals. However, a network can relatively be tightly regulated in one phenotype,
whereas it can be loosely regulated in another phenotype, and this represents
the deregulation of the given network.
mRNA Expression of ACSS1 and ACSS2 in Murine and Human HCC
Samples
Total RNA was isolated from tumor area and noncancerous area of liver tissue
samples obtained from six DEN-treated (HCC) CB1R
+/+ mice and six CB1R
/
mice (Mukhopadhyay et al., 2015). Total RNA was also isolated from noncan-
cerous and tumor biopsies from four different additional human donors with
HCC diagnosis without viral hepatitis. rRNA-depleted RNA, 100 ng for each
sample, was treated with RNase III to generate 100- to 200-nt fragments,
which were pooled and processed for RNA sequencing. All data were normal-
ized based on housekeeping genes used by Program CLC Genomics Work-
bench program (version 5.1, CLC Bio). These absolute numbers were
extracted from the reads, and the data were adjusted to non-HCC biopsies
for each gene.
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